SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bal Pharma reports 73.02% rise in Q4 consolidated net profit

31 May 2019 Evaluate

Bal Pharma has reported results for the fourth quarter and year ended March 31, 2019. 

The company has reported more than two fold rise in its net profit at Rs 3.57 crore for the quarter ended March 31, 2019 as compared to Rs 1.47 crore for the same quarter in the previous year. However, total income of the company decreased by 1.11% at Rs 57.03 crore for quarter under review as compared to Rs 57.67 crore for the quarter ended March 31, 2018.

On consolidated basis, the company has reported marginal rise of 73.02% in its net profit at Rs 1.09 crore for the quarter ended March 31, 2019 as compared to Rs 0.63 crore for the corresponding quarter in the FY18. Total consolidated income of the company decreased 2.83% at Rs 54.21 crore for quarter under review as compared to Rs 55.79 crore for the same quarter ended previous year.

For the year ended March 31, 2019, the company has posted a rise of 10.29% in its net profit at Rs 6.54 crore as compared to Rs 5.93 crore for the previous year. Total income of company increased 6.77% at Rs 225.79 crore for year under review as compared to Rs 211.48 crore for year ended March 31, 2018.

For the year ended March 31, 2019, on the consolidated basis, the company has posted more than five-fold rise in its net profit at Rs 1.94 crore as compared to Rs 0.37 crore for the previous year. Total income of company increased by 6.01% at Rs 225.99 crore for year under review as compared to Rs 213.17 crore for year ended March 31, 2018.


Bal Pharma Share Price

78.50 0.40 (0.51%)
20-Apr-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.00
Dr. Reddys Lab 1238.60
Cipla 1237.00
Zydus Lifesciences 940.85
Lupin 2331.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×